Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 20/20 | 0.80 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.58 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL448012 | 0.92 | MAPK14 (0.81) | MAPK14RPS6KA5CYP3A4MAPKAPK2KCNH2 | |
| SCHEMBL447903 | 0.89 | MAPK14 (1.00) | MAPK14 | |
| SCHEMBL448204 | 0.88 | MAPK14 (0.82) | MAPK14RPS6KA5CYP3A4MAPKAPK2KCNH2 | |
| SCHEMBL448394 | 0.87 | MAPK14 (0.80) | MAPK14RPS6KA5CYP3A4MAPKAPK2KCNH2 | |
| SCHEMBL450174 | 0.86 | MAPK14 (0.88) | MAPK14 | |
| SCHEMBL438814 | 0.86 | MAPK14 (0.79) | MAPK14RPS6KA5CYP3A4MAPKAPK2KCNH2 | |
| SCHEMBL437967 | 0.86 | MAPK14 (0.79) | MAPK14RPS6KA5CYP3A4MAPKAPK2KCNH2 | |
| SCHEMBL27813618 | 0.86 | MAPK14 (0.79) | MAPK14RPS6KA5CYP3A4MAPKAPK2KCNH2 | |
| SCHEMBL448006 | 0.85 | MAPK14 (0.86) | MAPK14 | |
| SCHEMBL453362 | 0.85 | MAPK14 (0.83) | MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210040062-A1 | AZOLE-SUBSTITUTED PYRIDINE COMPOUND | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2021-02-11 | — | — | US | disclosed |
| EP-3418276-A1 | AZOLE-SUBSTITUTED PYRIDINE COMPOUND | Taisho Pharmaceutical Co., Ltd. (JP) | 2018-12-26 | — | — | EP | disclosed |
| US-9206173-B2 | Heterocyclic compounds for the treatment of stress-related conditions | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-12-08 | — | — | US | disclosed |
| US-9067931-B2 | 2-heteroaryl carboxamides | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-06-30 | — | — | US | disclosed |
| US-20150073136-A1 | PYRAZINONE DERIVATIVES | ASTRAZENECA AB (SE) | 2015-03-12 | — | — | US | disclosed |
| US-20140350008-A1 | 2-HETEROARYL CARBOXAMIDES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-11-27 | — | — | US | disclosed |
| US-8889692-B2 | Pyrazinone derivatives, pharmaceutically acceptance salts thereof and their uses | ASTRAZENECA AB (SE) | 2014-11-18 | — | — | US | disclosed |
| EP-2170848-B1 | PYRAZINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF LUNG DISEASES | ASTRAZENECA AB (SE) | 2014-10-22 | — | — | EP | disclosed |
| EP-2435046-B1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF STRESS-RELATED CONDITIONS | OTSUKA PHARMA CO LTD (JP) | 2013-09-04 | — | — | EP | disclosed |
| CN-101842361-B | Pyrazinone derivatives and their use in the treatment of lung diseases | ASTRAZENECA AB | 2013-06-05 | — | — | CN | disclosed |
| WO-2010115758-A2 | FUNGICIDAL COMPOUNDS | BASF SE (DE) | 2010-10-14 | — | — | WO | disclosed |
| CN-101842361-A | Pyrazinone derivatives and their use in the treatment of lung diseases | ASTRAZENECA AB | 2010-09-22 | — | — | CN | disclosed |
| US-20100105731-A2 | NOVEL BENZAMIDINE COMPOUND | AJINOMOTO CO., INC. (JP) | 2010-04-29 | — | — | US | disclosed |
| US-20080255111-A1 | Tissue Factor Production Inhibitor | SANKYO COMPANY LIMITED (JP) | 2008-10-16 | — | — | US | disclosed |
| US-20080021065-A1 | NOVEL BENZAMIDINE COMPOUND | AJINOMOTO CO. INC (JP) | 2008-01-24 | — | — | US | disclosed |
| US-20080004301-A1 | Benzene Compound Having 2 or More Substituents | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2008-01-03 | — | — | US | disclosed |
| EP-1847527-A1 | NOVEL BENZAMIDINE COMPOUND | Ajinomoto Co., Inc. (JP) | 2007-10-24 | — | — | EP | disclosed |
| EP-1806332-A1 | BENZENE COMPOUND HAVING 2 OR MORE SUBSTITUENTS | Daiichi Sankyo Company, Limited (JP) | 2007-07-11 | — | — | EP | disclosed |
| EP-1764075-A1 | TISSUE FACTOR PRODUCTION INHIBITOR | Sankyo Company, Limited (JP) | 2007-03-21 | — | — | EP | disclosed |
| US-20060160877-A1 | 2-Heteroaryl carboxamides | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2006-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105731-A2 | NOVEL BENZAMIDINE COMPOUND | SERPINC1, F11, TFPI | MAPK14 171/4885RPS6KA5 2784/4885CYP3A4 1674/4885 |
| US-20140350008-A1 | 2-HETEROARYL CARBOXAMIDES | GRIN2A, CNR2, GRIN2C | MAPK14 1851/4885RPS6KA5 2469/4885CYP3A4 1069/4885 |
| US-20080255111-A1 | Tissue Factor Production Inhibitor | PTAFR, PLAT, TFPI | MAPK14 1233/4885RPS6KA5 2244/4885CYP3A4 3582/4885 |
| US-20060160877-A1 | 2-Heteroaryl carboxamides | GRIN2A, CNR2, GRIN2C | MAPK14 1851/4885RPS6KA5 2469/4885CYP3A4 1069/4885 |
| US-20150073136-A1 | PYRAZINONE DERIVATIVES | CYP3A7, CYP3A4, CYP2D6 | MAPK14 3325/4885RPS6KA5 54/4885CYP3A4 2/4885 |
| US-20210040062-A1 | AZOLE-SUBSTITUTED PYRIDINE COMPOUND | CYP2F1, CYP21A2, CYP11B1 | MAPK14 480/4885RPS6KA5 1846/4885CYP3A4 68/4885 |
| US-20080021065-A1 | NOVEL BENZAMIDINE COMPOUND | SERPINC1, F11, TFPI | MAPK14 171/4885RPS6KA5 2784/4885CYP3A4 1674/4885 |
| US-20080004301-A1 | Benzene Compound Having 2 or More Substituents | NR1H2, NR1H3, NCOR2 | MAPK14 2689/4885RPS6KA5 2858/4885CYP3A4 233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.